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Introduction {#sec004}
============

As a rapidly evolving procedure, transcatheter aortic valve implantation (TAVI) has been shown to be a safe and effective alternative to surgical aortic valve replacement (SAVR) in high-risk or inoperable patients with symptomatic aortic stenosis (AS) \[[@pone.0119817.ref001]--[@pone.0119817.ref003]\]. These aging patients frequently have a high prevalence of chronic renal dysfunction (RD), which portends a poor prognosis in those who undergo SAVR \[[@pone.0119817.ref002]--[@pone.0119817.ref004]\]. However, the results from studies evaluating the impact of baseline renal function on outcomes after TAVI are conflicting \[[@pone.0119817.ref005]--[@pone.0119817.ref007]\]. In many TAVI studies, although higher mid-term mortality were observed in patients with RD, these differences were not found to be significant by multivariate analyses \[[@pone.0119817.ref006], [@pone.0119817.ref008]--[@pone.0119817.ref010]\]. In addition, the relationship between varying degrees of RD and mid-term prognosis has also not been elucidated.

Therefore, we conducted a meta-analysis of published studies to clarify the mid-term prognostic value of preexisting RD in patients undergoing TAVI.

Materials and Methods {#sec005}
=====================

Search Strategy {#sec006}
---------------

The PubMed online database and the Cochrane library were searched for articles published from January 2002 to April 2014. The following search strategy was used: (transcatheter OR percutaneous OR transfemoral OR transapical OR transsubclavian OR transaortic OR transaxillary) AND (aortic valve) AND (implantation OR replacement) AND (risk factor OR risk assessment OR predictor OR kidney disease OR renal insufficiency OR nephropathy OR creatinine OR estimated glomerular filtration rate OR dialysis OR hemodialysis OR hemodialysis). Reference lists of comparable articles were also retrieved to seek potentially relevant citations.

Study Selection {#sec007}
---------------

Two reviewers conducted the initial screening of titles and abstracts; full-length reports of identified studies were retrieved; and decisions were then made regarding eligibility according to pre-specified inclusion and exclusion criteria. Studies were included if they (1) reported the predictive value of the pre-procedure renal function or mortality outcomes in patients with RD compared with normal controls; (2) performed follow-ups for at least 6 months; and (3) were human studies and published in English. Studies were excluded if they were (1) abstracts, letters, editorials, or reviews and (2) duplicate publications. Studies with overlapping populations were handled by selecting the study that reported on the largest sample of patients undergoing TAVI, unless they used different definitions of RD or reported results in different analysis models.

Data Extraction {#sec008}
---------------

Data were extracted from relevant studies using a pre-specified data collection form that included the first author, journal, year of publication, baseline characteristics, definition of RD, valve type, follow-up duration, and number of complications and deaths. Complications were defined according to the Valve Academic Research Consortium criteria \[[@pone.0119817.ref011]\], including acute kidney injure (AKI), stroke, all-cause bleeding, and major vascular complications. The outcomes from 6 months to 3 years were defined as mid-term outcomes. The incidence of all-cause mid-term mortality was the primary end point. TAVI-related complications were also the end points of interest.

Definitions of RD {#sec009}
-----------------

RD was defined as a diagnosis of chronic kidney disease (CKD), chronic renal failure, renal insufficiency, decreased estimated glomerular filtration rate (eGFR), or elevated serum creatinine level at baseline. CKD stages were classified according to baseline eGFR as follows \[[@pone.0119817.ref012]\]: ≥60 ml/min (normal or mild CKD, stage 1+2), 30--59 ml/min (moderate CKD, stage 3), 15--29 ml/min (severe CKD, stage 4), and \<15 ml/min or dialysis (kidney failure, stage 5). Advanced CKD was defined as CKD stage 3--5.

Statistical Analysis {#sec010}
--------------------

The hazard ratio (HR) of preexisting RD with regard to mid-term mortality after TAVI was extracted or calculated. The Generic Invers Variance method in the RevMan software, version 5.20 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for synthesis of the effect estimates. Heterogeneity was assessed by the *Q*-statistic and *I* ^2^ test. The fixed effects model was selected for the analysis without significant heterogeneity (*I* ^2^\<50% and a corresponding *P*\>0.1); otherwise, the random effects model was used to obtain the combined effect estimates. Statistical significance was set at *P*\<0.05 (two-tailed). Sensitivity analyses were performed using the STATA software version 12.1 (StataCorp, College Station, TX) to test the robustness of the results and the influence of potential effect modifiers. Publication bias was assessed by graphical inspection of funnel plots, Begg's tests, and Egger's tests. The "Trim and Fill method" was applied if there was any evidence of publication bias \[[@pone.0119817.ref013]\].

The present meta-analysis was conducted and reported according to the recommendation of the MOOSE group \[[@pone.0119817.ref014]\].

Results {#sec011}
=======

Study Selection {#sec012}
---------------

We identified 1096 citations in the initial screening ([Fig. 1](#pone.0119817.g001){ref-type="fig"}). After removing duplicates and screening at the abstract level, we retrieved 286 articles for a more detailed evaluation. While 239 studies were subsequently excluded, a total of 47 full-text articles were eligible for this meta-analysis, enrolling a total of 32,131 AS patients with renal function-specific data. No significant limitations were identified for the 47 trials, 3 of which were randomized comparisons \[[@pone.0119817.ref015]--[@pone.0119817.ref017]\], while others were observational cohort studies \[[@pone.0119817.ref005], [@pone.0119817.ref006], [@pone.0119817.ref018]--[@pone.0119817.ref056]\]. Although a few studies had overlapping patient populations, they provided different outcomes according to different definitions of RD, as defined by the author \[[@pone.0119817.ref016], [@pone.0119817.ref018], [@pone.0119817.ref020], [@pone.0119817.ref023], [@pone.0119817.ref040], [@pone.0119817.ref042], [@pone.0119817.ref043]\], baseline eGFR \[[@pone.0119817.ref010], [@pone.0119817.ref027], [@pone.0119817.ref049]\], or serum creatinine \[[@pone.0119817.ref006], [@pone.0119817.ref015], [@pone.0119817.ref017], [@pone.0119817.ref034], [@pone.0119817.ref035], [@pone.0119817.ref038], [@pone.0119817.ref047], [@pone.0119817.ref056]\]. We thus assigned these studies to different groups for either univariate or multivariate analysis.

![Meta-analysis flow diagram of study selection.](pone.0119817.g001){#pone.0119817.g001}

Study and Patient Characteristics {#sec013}
---------------------------------

The baseline features of the included patients are presented in [Table 1](#pone.0119817.t001){ref-type="table"}. Most studies were conducted in the general population, while a few studies performed TAVI in unique patient groups, such as octogenarians and nonagenarians \[[@pone.0119817.ref043]\], patients at very high risk (with a EuroSCORE of more than 40%) \[[@pone.0119817.ref042]\], and patients with chronic lung disease (CLD) \[[@pone.0119817.ref015]\]. Four studies elucidated the impact of detailed CKD classification on outcomes after TAVI \[[@pone.0119817.ref010], [@pone.0119817.ref029], [@pone.0119817.ref048], [@pone.0119817.ref049]\]. Patients with end-stage renal disease (ESRD) were included in 14 studies \[[@pone.0119817.ref005], [@pone.0119817.ref018], [@pone.0119817.ref022]--[@pone.0119817.ref024], [@pone.0119817.ref029], [@pone.0119817.ref038]--[@pone.0119817.ref041], [@pone.0119817.ref043], [@pone.0119817.ref047], [@pone.0119817.ref053], [@pone.0119817.ref055], [@pone.0119817.ref056]\] and were excluded in 7 studies \[[@pone.0119817.ref006], [@pone.0119817.ref010], [@pone.0119817.ref015]--[@pone.0119817.ref017], [@pone.0119817.ref044], [@pone.0119817.ref049]\]. In the remaining studies, the number of patients with ESRD was unclear. Procedural characteristics and the main outcomes after TAVI are summarized in [Table 2](#pone.0119817.t002){ref-type="table"}.

10.1371/journal.pone.0119817.t001

###### Baseline characteristics of included patients.

![](pone.0119817.t001){#pone.0119817.t001g}

  Study                                                     n                                            Male (%)   Age(y)                                             STS Score         Logistic Euroscore                                Hypertension (%)                             Diabetes mellitus (%)                         Previous CAD (%)                              Previous CE (%)                              Renal dysfunction, n (%) / Baseline renal function                                                                                                                                                       LVEF (%)                         Mean AVA (cm^2^)                                    Mean gradient (mmHg)   
  --------------------------------------------------------- -------------------------------------------- ---------- -------------------------------------------------- ----------------- ------------------------------------------------- -------------------------------------------- --------------------------------------------- --------------------------------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- --------------------------------------------------- ---------------------- ------------------
  Unbehaun *et al*, 2011 \[[@pone.0119817.ref018]\]         300                                          32.3       79.6±8.1                                           19.1±15.5         38.5±19.4                                         N/A                                          24.0                                          59.3                                          32.7                                         Chronic Renal Failure; Baseline eGFR[^a^](#t001fn002){ref-type="table-fn"} = 52.0±24.5ml/min/1.73m^2^                                                                                                    Included                         EF\<25: 9.3                                         0.7±0.2                48.5±14.9
  Tzikas *et al*, 2011 \[[@pone.0119817.ref019]\]           63                                           43         82(78--86)                                         5(3--8)           15(11--19)                                        57                                           22                                            N/A                                           24                                           Chronic Renal Disease/Insufficiency; n = 13(21)                                                                                                                                                          Unclear                          49±14                                               N/A                    47±19
  Sinning *et al*, 2012 \[[@pone.0119817.ref020]\]          146                                          47.9       80.5±6.6                                           9.8±7.3           30.2±18.0                                         N/A                                          N/A                                           61.0                                          25.3                                         Chronic Renal Failure; n = 82(56.2)                                                                                                                                                                      Unclear                          44.5±14.5                                           0.67±0.15              38.0(29.0--51.0)
  Vasa-Nicotera *et al*, 2012 \[[@pone.0119817.ref021]\]    122                                          53.3       81.7±6.8                                           7.3±4.3           22.4±13.0                                         N/A                                          N/A                                           62.3                                          16.4                                         Chronic Renal Failure; n = 48(39.3)                                                                                                                                                                      Unclear                          49.9±10.9                                           0.64±0.19              44.2±15.8
  Wendler *et al*, 2013 \[[@pone.0119817.ref022]\]          1387                                         41.5       80.6±7.1                                           N/A               27.6±16.1                                         68.9                                         28.6                                          55.9                                          15.2                                         Renal insufficiency/failure; n = 432(31.2)                                                                                                                                                               18 patients receiving dialysis   EF\<30: 5.7                                         N/A                    N/A
  Chopard *et al*, 2014 \[[@pone.0119817.ref023]\]          3933[^b^](#t001fn003){ref-type="table-fn"}   51         82.8±7.1                                           14.1±11.7         21.8±14.1                                         69                                           26                                            48                                            10                                           Chronic Kidney Disease; n = 336(9)                                                                                                                                                                       Included                         EF\<30: 7.0                                         N/A                    N/A
  Muñoz-García *et al*, 2013 \[[@pone.0119817.ref024]\]     1220[^c^](#t001fn004){ref-type="table-fn"}   45.3       80.7±6.3                                           N/A               17.8±13                                           79.4                                         31.2                                          36.1                                          11.1                                         Oliguric Renal Failure; n = 17(1.5)                                                                                                                                                                      15 patients receiving dialysis   55.8±14                                             0.62±0.18              51.6±18
  Godino *et al*, 2010 \[[@pone.0119817.ref025]\]           137                                          53.3       79.5±6.7                                           7.1±4.6           27.4±16.7                                         N/A                                          29.2                                          N/A                                           22.6                                         eGFR\<60ml/min/1.73m^2^; n = 51(37.2)                                                                                                                                                                    Unclear                          50.9±12.6                                           N/A                    52.3±17.3
  Rodés-Cabau *et al*, 2010 \[[@pone.0119817.ref005]\]      339                                          44.8       81± 8                                              9.8±6.4           N/A                                               74.3                                         23.3                                          69.0                                          22.7                                         eGFR\<60ml/min/1.73m^2^; n = 191(56.3); Baseline creatinine = 119±83umol/l                                                                                                                               10 patients receiving dialysis   55±14                                               0.63±0.17              46±17
  Hayashida *et al*, 2012 \[[@pone.0119817.ref026]\]        400                                          48.5       83.4±6.1                                           7.9(5.1--12.3)    22.3(17.1--30.3)                                  69.0                                         23.0                                          59.3                                          10.3                                         eGFR\<60ml/min/1.73m^2^; n = 249(63)                                                                                                                                                                     Unclear                          54.7±12.3                                           0.62±0.15              47.8±17.1
  Sinning *et al*, 2012 \[[@pone.0119817.ref027]\]          152                                          49.3       80.5±6.5                                           9.8±7.3           30.4±18.1                                         N/A                                          N/A                                           61.2                                          24.3                                         eGFR[^d^](#t002fn005){ref-type="table-fn"}\<60ml/min/1.73m^2^; n = 87(57.2); Baseline eGFR = 52±21 ml/min/1.73m^2^                                                                                       Unclear                          44.2±14.5                                           0.67±0.15              38.0(29.0--51.0)
  Nombela-Franco *et al*, 2012 \[[@pone.0119817.ref008]\]   1061                                         50.7       81±8                                               6.5(4.3--9.7)     N/A                                               74.5                                         29.4                                          64.7                                          18.1                                         eGFR\<60ml/min/1.73m^2^; Baseline eGFR = 60.1±27.8ml/min/1.73m^2^                                                                                                                                        Unclear                          EF\<40: 22.1                                        0.66±0.19              43±16
  Kamaga *et al*, 2013 \[[@pone.0119817.ref028]\]           30                                           53.3       86±3                                               N/A               34±12                                             86.7                                         20                                            N/A                                           16.7                                         eGFR[^d^](#t002fn005){ref-type="table-fn"}\<60ml/min/1.73m^2^; n = 18(60); Baseline eGFR = 52±17 ml/min/1.73m^2^                                                                                         Unclear                          52±14                                               N/A                    N/A
  Dumonteil *et al*, 2013 \[[@pone.0119817.ref029]\]        942                                          53.8       81.0±7.0                                           N/A               20.9(12.9--28.9)                                  69.5                                         28.5                                          45.2                                          15.7                                         Chronic Kidney Disease: Mild = 329(eGFR[^d^](#t002fn005){ref-type="table-fn"} = 60--89ml/min); Moderate = 399(eGFR = 30--59ml/min); Severe = 72(eGFR \<30ml/min)                                         33 patients receiving dialysis   EF\<35: 17                                          N/A                    N/A
  Mok *et al*, 2013 \[[@pone.0119817.ref009]\]              319                                          46.1       80±8                                               6.3(4.1--8.9)     N/A                                               89.0                                         37.3                                          63.9                                          19.1                                         eGFR\<60ml/min/1.73m^2^; n = 192(60.2)                                                                                                                                                                   Unclear                          54 ± 14                                             n = 192(60.2)          40±16
  Zahn *et al*, 2013 \[[@pone.0119817.ref030]\]             1318                                         41.5       81.7±6.1                                           N/A               20.3±13.5                                         N/A                                          34.1                                          N/A                                           8.1                                          eGFR\<60ml/min/1.73m^2^; n = 798/1318(60.5)                                                                                                                                                              Unclear                          53.5±14.7                                           0.66±0.24              46\. 3±21.8
  Urena *et al*, 2014 \[[@pone.0119817.ref031]\]            1556                                         47.6       80.2±7.6                                           7.6±5.3-          20.5±14                                           81.4                                         31.2                                          56.4                                          N/A                                          eGFR\<60ml/min/1.73m^2^; n = 882 (56.7)                                                                                                                                                                  Unclear                          55.2±13.9                                           N/A                    47.3±16
  Panico *et al*, 2012 \[[@pone.0119817.ref032]\]           118                                          46.6       82.5±5.87                                          N/A               25.8±15.4                                         80.5                                         28.8                                          51.7                                          5.9                                          eGFR\<60ml/min/1.73m^2^; n = 53(44.9); eGFR\<30ml/min/1.73m^2^; n = 9(7.6)                                                                                                                               Unclear                          EF\<30: 5.9                                         0.75±0.15              50.9±20.6
  Katsanos *et al*, 2013 \[[@pone.0119817.ref033]\]         116                                          49         81±8                                               N/A               21.2±12.3                                         41                                           27                                            65                                            N/A                                          Creatinine\>106umol/l; n = 41(35)                                                                                                                                                                        Unclear                          54±14                                               N/A                    N/A
  Tamburino *et al*, 2011 \[[@pone.0119817.ref034]\]        663                                          44         81.0 ± 7.3                                         N/A               23.0±13.7                                         75.1                                         26.4                                          48.3                                          7.2                                          Creatinine\>133umol/l; n = 154(23.2)                                                                                                                                                                     Unclear                          51.2±25.5                                           N/A                    51.8±17.0
  Barbanti *et al*, 2014 \[[@pone.0119817.ref035]\]         518                                          55.1       81.5±8.4                                           8.3±5.2           N/A                                               77.6                                         30.1                                          N/A                                           14.7                                         Creatinine\>177umol/l; n = 197(38)                                                                                                                                                                       Unclear                          53.9±13.9                                           0.7±0.4                42.2 ±16.3
  Dvir *et al*, 2014 \[[@pone.0119817.ref015]\]             1108                                         54.4       82.7±7.2                                           11.9±4.1          27.2±16.5                                         N/A                                          N/A                                           76.6                                          28.4                                         Creatinine\>177umol/l; n = 182(16.4)                                                                                                                                                                     Excluded                         53.1±12.8                                           0.66±0.19              42.3±14.1
  Moat *et al*, 2011 \[[@pone.0119817.ref036]\]             870                                          52.4       81.9±7.1                                           N/A               18.5(11.7--27.9)                                  N/A                                          22.8                                          47.6                                          N/A                                          Creatinine\>200umol/l; n = 55(6.7)                                                                                                                                                                       Unclear                          N/A                                                 N/A                    N/A
  Seiffert *et al*, 2013 \[[@pone.0119817.ref037]\]         326                                          44.5       80.6(79.8--81.3)                                   8.3(7.7--8.9)     22.7(21.2--24.2)                                  N/A                                          N/A                                           61.7                                          19.3                                         Creatinine\>200umol/l; n = 29(8.9); Baseline creatinine = 1.5(1.3--1.6)mg/dl                                                                                                                             Unclear                          N/A                                                 0.7(0.7--0.7)          36.5(34.6--38.4)
  Luçon et a*l*, 2014 \[[@pone.0119817.ref038]\]            2435                                         49.8       83±7                                               N/A               N/A                                               69                                           24.4                                          47.4                                          10.4                                         Creatinine\>200umol/l; n = 228(9.4)                                                                                                                                                                      63 patients receiving dialysis   52.8±14.6                                           N/A                    47.8±16.8
  Heinz *et al*, 2014 \[[@pone.0119817.ref039]\]            110                                          46.4       83(58--97)[^e^](#t001fn006){ref-type="table-fn"}   N/A               10(2--40)[^e^](#t001fn006){ref-type="table-fn"}   92                                           N/A                                           N/A                                           28                                           Renal impairment; n = 9(8)                                                                                                                                                                               3 patients receiving dialysis    50(11--73) [^e^](#t001fn006){ref-type="table-fn"}   N/A                    N/A
  Web *et al*, 2009 \[[@pone.0119817.ref040]\]              168                                          51.8       84(79--87)                                         9.1(6.3--13.0)    28.6(17.9--41.0)                                  64.9                                         23.2                                          67.9                                          17.9                                         Chronic Renal Failure; n = 20(11.9); Baseline creatinine = 98(81--130)umol/l                                                                                                                             Included                         EF\<35: 16.1                                        0.6(0.5--0.7)          46(34--55)
  Ben-Dor *et al*, 2012 \[[@pone.0119817.ref016]\]          159                                          42.7       84.4±5.8                                           11.8±3.9          42.3±21.4                                         89.3                                         32.0                                          57.2                                          27.0                                         Chronic Renal Failure; n = 64(40.2); Baseline creatinine = 1.3±1.6 mg/dl                                                                                                                                 Excluded                         51.2±15.9                                           0.6±0.18               55.3±21.1
  Nuis *et al*, 2012 \[[@pone.0119817.ref041]\]             235                                          49         80±7                                               6.1±5.5           19.1±13.7                                         56                                           24                                            N/A                                           N/A                                          Chronic Renal Failure; Baseline creatinine = 123±131umol/l                                                                                                                                               11 patients receiving dialysis   EF\<30: 14; 30--59: 35                              0.67±0.21              N/A
  Drews *et al*, 2013 \[[@pone.0119817.ref042]\]            186                                          34.4       81±8                                               23±14             63±16                                             N/A                                          28.5                                          71.5                                          42.5                                         Kidney Failure; Baseline creatinine = 1.5±1.0 mg/dl                                                                                                                                                      Unclear                          42±16                                               0.7±0.2                44±17
  Yamamoto *et al*, 2014 \[[@pone.0119817.ref043]\]         2254                                         47.5       86.3±3.5                                           N/A               23.6±16.8                                         69.9[^f^](#t001fn007){ref-type="table-fn"}   21.9 [^f^](#t001fn007){ref-type="table-fn"}   48.6 [^f^](#t001fn007){ref-type="table-fn"}   9.4 [^f^](#t001fn007){ref-type="table-fn"}   Renal Insufficiency; n = 200(9.13)[^f^](#t001fn007){ref-type="table-fn"}                                                                                                                                 41 patients receiving dialysis   53.7±13.8                                           0.66±0.18              49.1±16.9
  Saia *et al*, 2013 \[[@pone.0119817.ref044]\]             102                                          39.2       83.7±5.3                                           8.2±4.1           22.6±12.4                                         80.4                                         22.5                                          50                                            4.9                                          eGFR[^a^](#t001fn002){ref-type="table-fn"}\<30ml/min/1.73m^2^; n = 29(28.4)                                                                                                                              Excluded                         59.9±11.6                                           0.6±0.1                46.0±16.7
  Conrotto *et al*, 2014 \[[@pone.0119817.ref045]\]         511                                          50.5       N/A                                                N/A               N/A                                               91.2                                         29.4                                          N/A                                           14.3                                         eGFR\<30ml/min/1.73m^2^; n = 93(18.2)                                                                                                                                                                    Unclear                          N/A                                                 N/A                    N/A
  Sinning *et al*, 2010 \[[@pone.0119817.ref006]\]          77                                           48         80.8±6.7                                           9.3±6.1           31.2±17.6                                         94                                           23                                            65                                            26                                           eGFR[^d^](#t002fn005){ref-type="table-fn"}\<60ml/min/1.73m^2^; n = 48(62.3); Baseline eGFR = 50.6(38.2±63.8)ml/min/1.73m^2^                                                                              Excluded                         45.3±16.8                                           N/A                    N/A
  Tamburino *et al*, 2012 \[[@pone.0119817.ref046]\]        218                                          46.3       80.9±5.2                                           5.5±4.3           21.1±14.2                                         85.3                                         24.3                                          N/A                                           13.8                                         Creatinine\>133umol/l; n = 51(23.4)                                                                                                                                                                      Unclear                          51.1±10.6                                           0.8±0.2                58.2±16.8
  Van Belle *et al*, 2014 \[[@pone.0119817.ref047]\]        2769                                         51.1       82.7±7.2                                           N/A               21.5±13.8                                         70                                           25.2                                          47.1                                          9.5                                          Creatinine\>200umol/l; n = 233(8.4)                                                                                                                                                                      Included                         N/A                                                 0.68±0.18              48.4±16.3
  Nguyen *et al*, 2013 \[[@pone.0119817.ref048]\]           321                                          55.8       82.2±8.2                                           12.1±7.3          N/A                                               95.1                                         43.6                                          N/A                                           32.1                                         Chronic Kidney Disease: Normal/Mild = 159(eGFR[^d^](#t002fn005){ref-type="table-fn"}≥60ml/min); Moderate = 139(eGFR = 30--59ml/min); Severe = 23(eGFR\<30ml/min);                                        8 patients receiving dialysis    48.2±14.2                                           N/A                    N/A
  Yamamoto *et al*, 2013 \[[@pone.0119817.ref049]\]         642                                          48.1       83.5±6.5                                           N/A               22.9±12.2                                         70.6                                         22.6                                          N/A                                           9.8                                          Chronic Kidney Disease: Stage1--2 = 218(eGFR[^d^](#t002fn005){ref-type="table-fn"}≥60ml/min); Stage3a = 182(eGFR = 45--59ml/min); Stage3b = 181(eGFR = 30--44ml/min); Stage4 = 61(eGFR = 15--29ml/min)   Excluded                         52.7±14.8                                           0.64±0.17              47.6±17.5
  D\'Ascenzm *et al*, 2013 \[[@pone.0119817.ref010]\]       364                                          42.3       82.4±5.3                                           6.6±4.6           23.2±14.1                                         86.5                                         31.0                                          N/A                                           23.1                                         Chronic Kidney Disease; Moderate = 219(eGFR[^a^](#t001fn002){ref-type="table-fn"} = 30--59ml/min); Severe = 73(eGFR = 15--29ml/min)                                                                      Excluded                         52.4±11.9                                           0.62±0.18              53.2±17.3
  Lange *et al*, 2012 \[[@pone.0119817.ref050]\]            420                                          37         80.3±7.1                                           6.1±4.1           20.17±13.0                                        N/A                                          N/A                                           55                                            13.2                                         Baseline Creatinine = 1.20±0.56 mg/dl                                                                                                                                                                    Unclear                          EF\>50: 62.4; 35--50: 22.1; \<35: 15.5              N/A                    N/A
  Houthuizen *et al*, 2012 \[[@pone.0119817.ref051]\]       679                                          47         81(77--85)                                         N/A               16.0(10.0--25.0)                                  N/A                                          23.6                                          47.0                                          17.7                                         Baseline Creatinine = 1.07(0.85--1.38)mg/dl                                                                                                                                                              Unclear                          EF\<50: 28.0                                        0.7(0.6--0.8)          4(36--57)
  Gotzmann *et al*, 2012 \[[@pone.0119817.ref052]\]         198                                          47         80±6                                               N/A               22±16                                             N/A                                          N/A                                           52                                            N/A                                          Baseline Creatinine = 1.2±0.7 mg/dl                                                                                                                                                                      Unclear                          53±13                                               0.7±0.1                47±13
  Codner *et al*, 2013 \[[@pone.0119817.ref053]\]           153                                          37.9       82.1±6.0                                           9.2±5.3           22.5±13.2                                         90.2                                         29.4                                          N/A                                           18.3                                         Baseline eGFR = 66.7±27.3ml/min/1.73m^2^                                                                                                                                                                 3 patients with ESRD             N/A                                                 0.62±0.16              50.5±15.4
  Sabaté*et al*, 2013 \[[@pone.0119817.ref054]\]            1416                                         46         81±6                                               N/A               17±11                                             78                                           34                                            N/A                                           10                                           Baseline Creatinine = 1.26±0.7 mg/dl                                                                                                                                                                     Unclear                          56±13                                               0.6±0.2                50±15
  Linke *et al*, 2014 \[[@pone.0119817.ref055]\]            1015                                         49         81.1± 6.4                                          5.3(3.6--7.8)     16.0(10.3--25.3)                                  N/A                                          31.3                                          57.8                                          13.1                                         Baseline Creatinine = 1.25±0.75 mg/dl; Creatinine clearance\<20ml/min = 148(14.9)[^g^](#t001fn008){ref-type="table-fn"}                                                                                  Included                         53.3±13.7                                           0.7±0.3                45.6±15.5
  Unbehaun *et al*, 2014 \[[@pone.0119817.ref056]\]         730                                          39.9       80.1(75.3--84.4)                                   10.4(6.1--17.8)   28.8 (18.9--48.2)                                 N/A                                          29.3                                          61.2                                          22.2                                         Baseline Creatinine Clearance = 53.5(38.9--69.4)ml/min                                                                                                                                                   16 patients receiving dialysis   55.0(40.0--60.0)                                    0.6(0.6--0.8)          49.5(38.0--57.0)
  Kodali *et al*, 2012 \[[@pone.0119817.ref017]\]           348                                          57.8       83.6±6.8                                           11.8±3.3          29.3±16.5                                         N/A                                          N/A                                           74.9                                          29.3                                         Baseline Creatinine\>2mg/dl; n = 38(11.1)                                                                                                                                                                Excluded                         52.5±13.5                                           0.7±0.2                42.7±14.6

Data are presented as mean±SD or median (interquartile range) as appropriate. Abbreviation used: STS: Society of Thoracic Surgeons; EuroSCORE: European system for cardiac operative risk evaluation; CAD: coronary arterial disease; CE: cerebrovascular event; ESRD: end-stage renal disease; LVEF: left ventricular ejection fraction; AVA: aortic valve area; eGFR: estimated glomerular filtration rate.

a\. Calculated by Cockroft-Gault (CG) formula.

b\. Mid-term outcomes available in 3597 patients.

c\. Data available in 1116 patients.

d\. Calculated by Modification of Diet in Renal Disease (MDRD) formula.

e\. Data presented as median (minimal to max range).

f\. Data available in 2190 patients.

g\. Data available in 996 patients.

10.1371/journal.pone.0119817.t002

###### Procedure features and main outcomes of included studies.

![](pone.0119817.t002){#pone.0119817.t002g}

  Study                                                     Approach (%)   Valve type (%)   Follow-up             Peri-procedural complications                Death (%)                                                                Cardiovascular death (%)                                                                                                                                                                                                                                                      
  --------------------------------------------------------- -------------- ---------------- --------------------- -------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------- --------------------------------------------
  Unbehaun *et al*, 2011 \[[@pone.0119817.ref018]\]         N/A            N/A              EV: 100               11.7±8.7mo                                   N/A                                                                      1.3                                                                          N/A                                                                        N/A                                                                      65                                           N/A
  Tzikas *et al*, 2011 \[[@pone.0119817.ref019]\]           N/A            N/A              MCV: 100              383d(356--419)                               N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      28.6                                         N/A
  Sinning *et al*, 2012 \[[@pone.0119817.ref020]\]          91.8           N/A              MCV: 100              1y                                           AKI: 23.3                                                                N/A                                                                          7.5                                                                        5.5                                                                      26.7                                         N/A
  Vasa-Nicotera *et al*, 2012 \[[@pone.0119817.ref021]\]    97.5           1.7              EV: 20.5; MCV: 79.5   1y                                           N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      35.2                                         N/A
  Wendler *et al*, 2013 \[[@pone.0119817.ref022]\]          N/A            100              EV: 100               2y                                           Dialysis: 6.7                                                            3.9                                                                          2.6                                                                        2.5                                                                      34.9                                         N/A
  Chopard *et al*, 2014 \[[@pone.0119817.ref023]\]          73             18               EV: 66; MCV: 33       1y                                           AKI: 1.6                                                                 11                                                                           9.1                                                                        3.3                                                                      19.1                                         8.8
  Muñoz-García *et al*, 2013 \[[@pone.0119817.ref024]\]     91.4           N/A              MCV: 100              238d(50--480)                                AKI: 11                                                                  N/A                                                                          3.9                                                                        N/A                                                                      10.6                                         N/A
  Godino *et al*, 2010 \[[@pone.0119817.ref025]\]           78             11               EV: 57.7; MCV: 42.3   6mo                                          RRT: 8                                                                   N/A                                                                          16.8                                                                       0.7                                                                      13.1                                         5.1
  Rodés-Cabau *et al*, 2010 \[[@pone.0119817.ref005]\]      47.8           52.2             EV: 100               8mo(3--14)                                   Dialysis: 2.6                                                            N/A                                                                          13.3                                                                       2.4                                                                      22.1                                         N/A
  Hayashida *et al*, 2012 \[[@pone.0119817.ref026]\]        N/A            N/A              EV: 86.8; MCV: 13.2   279d(101--607)                               AKI: 9.0                                                                 N/A                                                                          8.8                                                                        6.5                                                                      27.3                                         N/A
  Sinning *et al*, 2012 \[[@pone.0119817.ref027]\]          92.1           N/A              MCV: 100              1y                                           AKI: 23.0                                                                9.2                                                                          8.6                                                                        5.3                                                                      27                                           N/A
  Nombela-Franco *et al*, 2012 \[[@pone.0119817.ref008]\]   68.4           30.3             EV: 64; MCV: 36       12mo(3--23)                                  N/A                                                                      N/A                                                                          2.1                                                                        N/A                                                                      37.8                                         N/A
  Kamaga *et al*, 2013 \[[@pone.0119817.ref028]\]           100            N/A              EV: 100               1y                                           AKI: 2.5                                                                 N/A                                                                          3.3                                                                        N/A                                                                      26.7                                         N/A
  Dumonteil *et al*, 2013 \[[@pone.0119817.ref029]\]        84.1           9.3              EV: 46.3; MCV: 53.7   1y                                           AKI in CKD stage 1+2: 25.7; In CKD stage 3: 23.3; In CKD stage 4: 45.8   CKD stage 1+2: 42.9; CKD stage 3: 56; CKD stage 4: 52.8; CKD stage 5: 42.4   CKD stage 1+2: 6.1; CKD stage 3: 16.7; CKD stage 4: 11; CKD stage 5: 9.6   CKD stage 1+2: 1.8; CKD stage 3: 3; CKD stage 4: 4.2; CKD stage 5: 6.1   18.8                                         N/A
  Mok *et al*, 2013 \[[@pone.0119817.ref009]\]              39.2           N/A              EV: 98.7              12mo(7--25)                                  N/A                                                                      10.7                                                                         N/A                                                                        3.1                                                                      29.5                                         14.4
  Zahn *et al*, 2013 \[[@pone.0119817.ref030]\]             88             8.6              EV: 17.9; MCV: 81.5   1y                                           N/A                                                                      N/A                                                                          N/A                                                                        2.8                                                                      21.8                                         N/A
  Urena *et al*, 2014 \[[@pone.0119817.ref031]\]            N/A            N/A              N/A                   22±17mo                                      N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      23.4                                         16.3
  Panico *et al*, 2012 \[[@pone.0119817.ref032]\]           116            N/A              EV: 69.5; MCV: 30.5   1y                                           AKI: 28.9                                                                22                                                                           5.1                                                                        7.6                                                                      17.8                                         N/A
  Katsanos *et al*, 2013 \[[@pone.0119817.ref033]\]         41             59               EV: 100               25mo(13--45)                                 N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      18.1                                         N/A
  Tamburino *et al*, 2011 \[[@pone.0119817.ref034]\]        90.3           N/A              MCV: 100              1y                                           N/A                                                                      N/A                                                                          1.96                                                                       1.2                                                                      17.2                                         N/A
  Barbanti *et al*, 2014 \[[@pone.0119817.ref035]\]         66.2           33.2             EV: 93.2; MCV: 3.1    2y                                           N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      22.8                                         5.8
  Dvir *et al*, 2014 \[[@pone.0119817.ref015]\]             N/A            N/A              N/A                   1y                                           N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      23.4                                         10.2
  Moat *et al*, 2011 \[[@pone.0119817.ref036]\]             68.9           N/A              EV: 47.1; MCV: 52.9   1y                                           N/A                                                                      N/A                                                                          4                                                                          N/A                                                                      21.4                                         N/A
  Seiffert *et al*, 2013 \[[@pone.0119817.ref037]\]         45.7           52.3             EV: 86.2; MCV: 13.8   1y                                           AKI: 29.4                                                                7.4                                                                          8.6                                                                        5.8                                                                      29.8                                         18.7
  Luçon et a*l*, 2014 \[[@pone.0119817.ref038]\]            74.9           17.5             EV: 67.3; MCV: 32.7   1y                                           N/A                                                                      N/A                                                                          1.6                                                                        N/A                                                                      16.4                                         10
  Heinz *et al*, 2014 \[[@pone.0119817.ref039]\]            45             44               N/A                   1y                                           AKI: 55.5                                                                N/A                                                                          5                                                                          2                                                                        27                                           N/A
  Web *et al*, 2009 \[[@pone.0119817.ref040]\]              79.2           20.7             EV: 100               221d[^a^](#t002fn002){ref-type="table-fn"}   AKI: 6.0; Dialysis: 1.8                                                  N/A                                                                          6.5                                                                        4.2                                                                      39.1                                         N/A
  Ben-Dor *et al*, 2012 \[[@pone.0119817.ref016]\]          69.1           30.9             EV: 100               399d(167--669)                               N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      30.8                                         7.5
  Nuis *et al*, 2012 \[[@pone.0119817.ref041]\]             97             3                MCV: 100              298d(107--688)                               AKI: 17                                                                  8.9                                                                          10.2                                                                       4.6                                                                      31.1                                         N/A
  Drews *et al*, 2013 \[[@pone.0119817.ref042]\]            N/A            100              EV: 100)              2y                                           N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      46                                           N/A
  Yamamoto *et al*, 2014 \[[@pone.0119817.ref043]\]         79.06          16.42            EV: 68.5; MCV: 31.5   1y                                           Dialysis: 1.4                                                            1.2                                                                          5                                                                          2.5                                                                      16.9[^b^](#t002fn003){ref-type="table-fn"}   N/A
  Saia *et al*, 2013 \[[@pone.0119817.ref044]\]             64.7           23.5             EV: 35.3; MCV: 64.7   1y                                           AKI: 41.2                                                                4.9                                                                          N/A                                                                        2                                                                        11.8                                         N/A
  Conrotto *et al*, 2014 \[[@pone.0119817.ref045]\]         57.7           23.3             EV: 53.2; MCV: 46.8   400d(178--715)                               AKI: 21.1                                                                43.1                                                                         7                                                                          1.8                                                                      20.4                                         11.9
  Sinning *et al*, 2010 \[[@pone.0119817.ref006]\]          100            N/A              MCV: 100              1y                                           AKI: 26                                                                  N/A                                                                          N/A                                                                        N/A                                                                      26                                           N/A
  Tamburino *et al*, 2012 \[[@pone.0119817.ref046]\]        97.2           1.8              EV: 11; MCV: 89       1y                                           N/A                                                                      5.5                                                                          N/A                                                                        2.3                                                                      12.4                                         N/A
  Van Belle *et al*, 2014 \[[@pone.0119817.ref047]\]        75.3           17.2             EV: 11; MCV: 89       306d(178--490)                               N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      11.3                                         6.3
  Nguyen *et al*, 2013 \[[@pone.0119817.ref048]\]           62             31               N/A                   4 y                                          Dialysis: 1.9                                                            CKD stage 1+2: 0.6; CKD stage 3: 1.4; CKD stage 4: 0                         N/A                                                                        CKD stage 1+2: 1.3; CKD stage 3: 1.4; CKD stage 4: 4.4                   N/A                                          N/A
  Yamamoto *et al*, 2013 \[[@pone.0119817.ref049]\]         67.1           N/A              EV: 62.9; MCV: 37.1   1y                                           AKI in CKD stage 1+2: 13.3; in CKD stage 3: 17.1; in CKD stage 4: 15     N/A                                                                          CKD stage 1+2: 7.3; CKD stage 3: 8.3; CKD stage 4: 9.8                     CKD stage 1+2: 1.8; CKD stage 3: 3.6; CKD stage 4: 8.2                   25.2                                         N/A
  D\'Ascenzm *et al*, 2013 \[[@pone.0119817.ref010]\]       69.5           5.8              N/A                   450±250d                                     AKI in CKD stage 1+2: 8; in CKD stage 3: 14; in CKD stage 4: 18          CKD stage 1+2: 20; CKD stage 3: 22; CKD stage 4: 33                          CKD stage 1+2: 10; CKD stage 3: 7; CKD stage 4: 10                         CKD stage 1+2: 1.4; CKD stage 3: 2.3; CKD stage 4: 4.1                   17.6                                         10.2
  Lange *et al*, 2012 \[[@pone.0119817.ref050]\]            61             31               EV: 30.6; MCV: 68.7   6mo                                          N/A                                                                      N/A                                                                          18.6                                                                       4.5                                                                      20                                           N/A
  Houthuizen *et al*, 2012 \[[@pone.0119817.ref051]\]       68.2           30.3             EV: 43; MCV: 57       450d[^a^](#t002fn002){ref-type="table-fn"}   N/A                                                                      N/A                                                                          N/A                                                                        N/A                                                                      28.7                                         N/A
  Gotzmann *et al*, 2012 \[[@pone.0119817.ref052]\]         N/A            N/A              MCV: 100              535±333d                                     Dialysis: 2.5                                                            N/A                                                                          N/A                                                                        2                                                                        27.8                                         16.7
  Codner *et al*, 2013 \[[@pone.0119817.ref053]\]           73.2           17.6             EV: 40.5; MCV: 59.5   2y                                           AKI: 5.2                                                                 2.6                                                                          1.3                                                                        3.9                                                                      11.8                                         4.6
  Sabaté*et al*, 2013 \[[@pone.0119817.ref054]\]            78.7           21.3             EV: 56.9; MCV: 43.1   244d[^c^](#t002fn004){ref-type="table-fn"}   AKI[^d^](#t002fn005){ref-type="table-fn"}: 1.0                           2.4                                                                          3                                                                          2.6                                                                      15.9                                         N/A
  Linke *et al*, 2014 \[[@pone.0119817.ref055]\]            88.4           2.1              MCV: 100              1y                                           AKI[^d^](#t002fn005){ref-type="table-fn"}: 6.0                           13.8                                                                         10.9                                                                       3                                                                        17.9[^e^](#t002fn006){ref-type="table-fn"}   11.7[^e^](#t002fn006){ref-type="table-fn"}
  Unbehaun *et al*, 2014 \[[@pone.0119817.ref056]\]         N/A            100              EV: 100               1.56y(0.40--2.69)                            AKI: 18.6; RRT: 3.0                                                      9.7                                                                          4                                                                          2.3                                                                      41.1                                         N/A
  Kodali *et al*, 2012 \[[@pone.0119817.ref017]\]           244            104              EV: 100               2y                                           AKI: 1.2                                                                 9.3                                                                          11                                                                         4.7                                                                      33.3                                         19.3

Data are presented as mean±SD or median (interquartile range) as appropriate. Abbreviation used: TF: trans-femoral; TA: trans-apical; MVC: major vascular complications; EV: Edwards Valve; MCV: Medtronic CoreValve; AKI: acute kidney injure; RRT: renal replacement therapy.

a\. Data presented as a median.

b\. Data available in 2249 patients.

c\. Data presented as a mean.

d\. Defined as stage 3 according to the Valve Academic Research Consortium (VARC).

e\. Data available in 996 patients.

Mid-Term Outcomes {#sec014}
=================

Mid-term Mortality according to Different Definitions of RD {#sec015}
-----------------------------------------------------------

### Defined by the Author {#sec016}

RD was defined by the author in 12 studies, in which either univariate \[[@pone.0119817.ref018]--[@pone.0119817.ref024]\] or multivariate \[[@pone.0119817.ref016], [@pone.0119817.ref020], [@pone.0119817.ref022], [@pone.0119817.ref040]--[@pone.0119817.ref043]\] analysis was performed. These studies enrolled 9769 patients, and the mid-term all-cause mortality rate was 23.6%. Patients with RD had a significantly higher risk for all-cause mortality at the mid-term follow-up (pooled univariate HR: 1.69; 95% CI: 1.50--1.90; pooled multivariate HR: 1.47; 95% CI: 1.17--1.84) compared with patients with normal renal function ([Fig. 2](#pone.0119817.g002){ref-type="fig"}). In the univariate model, the results were unchanged when individual studies were omitted or if the study included no more than 100 successful TAVI procedures \[[@pone.0119817.ref019]\] (pooled univariate HR: 1.67; 95% CI: 1.49--1.88). In the multivariate model, the pooled results also remained stable after removing studies in unique populations, such as patients with a EuroSCORE of more than 40% \[[@pone.0119817.ref042]\] (pooled multivariate HR: 1.45; 95% CI: 1.13--1.86), octogenarians and nonagenarians \[[@pone.0119817.ref043]\] (pooled multivariate HR: 1.51; 95% CI: 1.14--1.99), or patients without ESRD \[[@pone.0119817.ref016]\] (pooled multivariate HR: 1.42; 95% CI: 1.13--1.78).

![Forest plots of mid-term mortality associated with RD.\
A, Pooled univariate hazard ratio of patients without RD compared with patients with RD. B, Pooled multivariate hazard ratio of patients without RD compared with patients with RD. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; Random, Random-effects model; IV, Generic Inverse Variance method.](pone.0119817.g002){#pone.0119817.g002}

### Defined by eGFR {#sec017}

Thirteen studies that included a total of 6,980 patients defined RD as decreased baseline eGFR \[[@pone.0119817.ref005], [@pone.0119817.ref008], [@pone.0119817.ref009], [@pone.0119817.ref025]--[@pone.0119817.ref032], [@pone.0119817.ref044], [@pone.0119817.ref045]\]. The mid-term all-cause mortality rate was 24.5%. In patients with RD, mid-term mortality after TAVI was significantly increased compared with that in patients with normal renal function (pooled univariate HR: 1.65; 95% CI: 1.47--1.86; pooled multivariate HR: 1.46; 95% CI: 1.24--1.71) ([Fig. 3](#pone.0119817.g003){ref-type="fig"}). In the univariate analysis, the results remained unchanged after excluding the study with a small sample size \[[@pone.0119817.ref028]\] (pooled univariate HR: 1.65; 95% CI: 1.47--1.85) or the study that focused on patients with a baseline eGFR less than 30 ml/min/1.73 m^2^ \[[@pone.0119817.ref032]\] (pooled univariate HR: 1.65; 95% CI: 1.47--1.85). Sensitivity analysis of the multivariate model also confirmed the robustness of the results after deleting 2 studies that reported the impact of severe RD (eGFR\<30 ml/min/1.73 m^2^) on the mid-term outcomes \[[@pone.0119817.ref044], [@pone.0119817.ref045]\] (pooled multivariate HR: 1.39; 95% CI: 1.18--1.64).

![Forest plots of mid-term mortality associated with RD.\
A, Pooled univariate hazard ratio of patients without RD compared with patients with RD. B, Pooled multivariate hazard ratio of patients without RD compared with patients with RD. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; IV, Generic Inverse Variance method.](pone.0119817.g003){#pone.0119817.g003}

### Defined by Serum Creatinine {#sec018}

We identified 11 studies with mid-term mortality data in patients with elevated serum creatinine \[[@pone.0119817.ref006], [@pone.0119817.ref015], [@pone.0119817.ref033]--[@pone.0119817.ref039], [@pone.0119817.ref046], [@pone.0119817.ref047]\] ([Fig. 4](#pone.0119817.g004){ref-type="fig"}). The cumulative all-cause mortality rate of these 9210 patients was 17.2%. The pooled univariate HR suggested that patients with RD had a significantly higher mid-term mortality rate (pooled univariate HR: 1.69; 95% CI: 1.48--1.92) than patients with normal renal function. These results persisted when omitting individual studies or the study that reported outcomes in the CLD subgroup \[[@pone.0119817.ref015]\] (pooled univariate HR: 1.78; 95% CI: 1.54--2.05). This relationship was also observed in the multivariate model (pooled multivariate HR: 1.65; 95% CI: 1.36--1.99). After removing the relatively small study \[[@pone.0119817.ref006]\] (pooled multivariate HR: 1.58; 95% CI: 1.30--1.92) or the study that reported outcomes in the CLD subgroup \[[@pone.0119817.ref015]\] (pooled multivariate HR: 1.74; 95% CI: 1.39--2.17), the pooled results were still unchanged.

![Forest plots of mid-term mortality associated with RD.\
A, Pooled univariate hazard ratio of patients without RD compared with patients with RD. B, Pooled multivariate hazard ratio of patients without RD compared with patients with RD. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; IV, Generic Inverse Variance method.](pone.0119817.g004){#pone.0119817.g004}

Association of Mid-term Outcomes with Varying Degrees of RD {#sec019}
-----------------------------------------------------------

Four studies included a detailed classification of CKD according to the baseline eGFR \[[@pone.0119817.ref010], [@pone.0119817.ref029], [@pone.0119817.ref048], [@pone.0119817.ref049]\], and an additional 4 studies reported the mid-term mortality of patients on chronic dialysis \[[@pone.0119817.ref005], [@pone.0119817.ref022], [@pone.0119817.ref024], [@pone.0119817.ref038]\].

Compared with patients with CKD stage 1+2, patients with advanced CKD had significantly higher incidences of all-cause bleeding (univariate HR in CKD stage 3: 1.30, 95% CI: 1.13--1.49; in CKD stage 4: 1.30, 95% CI: 1.04--1.62), post-procedural AKI (univariate HR in CKD stage 3: 1.28, 95% CI: 1.03--1.59; in CKD stage 4: 2.27, 95% CI: 1.74--2.96), and stroke (univariate HR in CKD stage 4: 3.37, 95% CI: 1.52--7.46). Major vascular complications (MVC) were without significant difference according to baseline renal function status ([Fig. 5](#pone.0119817.g005){ref-type="fig"}). Compared with CKD stage 3, CKD stage 4 was strongly related to a higher incidence of AKI ((univariate HR: 1.70, 95% CI: 1.34--2.16), however, this difference was not significant when focusing on bleeding or stroke ([Fig. 6](#pone.0119817.g006){ref-type="fig"}). Sensitivity analyses were not conducted due to the small number of studies in each groups.

![Forest plots of peri-procedural complications associated with RD.\
A, Pooled univariate hazard ratio of patients without RD compared with patients with RD for all-cause bleeding. B, Pooled univariate hazard ratio of patients without RD compared with patients with RD for major vascular complications. C, Pooled univariate hazard ratio of patients without RD compared with patients with RD for acute kidney injure. D, Pooled univariate hazard ratio of patients without RD compared with patients with RD for stroke. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; IV, Generic Inverse Variance method.](pone.0119817.g005){#pone.0119817.g005}

![Patients with CKD stage 3 versus patients with CKD stage 4 for peri-procedural complications.\
A, Pooled univariate hazard ratio of CKD stage 3 compared with CKD stage 4 for all-cause bleeding. B, Pooled univariate hazard ratio of CKD stage 3 compared with CKD stage 4 for acute kidney injure. C, Pooled univariate hazard ratio of CKD stage 3 compared with CKD stage 4 for stroke. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; IV, Generic Inverse Variance method.](pone.0119817.g006){#pone.0119817.g006}

At mid-term follow-up, advanced CKD was significantly related to a poorer prognosis compared with CKD stage 1+2 (pooled univariate HR in CKD stage 3: 1.57, 95% CI: 1.26--1.95; in CKD stage 4: 2.77, 95% CI: 2.06--3.72; in CKD stage 5: 2.64, 95% CI: 1.91--3.65). Moreover, compared with patients with CKD stage 3, mortality was significantly increased in patients with CKD stage 4 (pooled univariate HR: 1.60, 95% CI: 1.28--1.99) ([Fig. 7](#pone.0119817.g007){ref-type="fig"}). These results persisted after omitting individual studies in the CKD stage 5 group. Due to the small number of studies, sensitivity analyses were not performed in the other groups.

![Patients with advanced stages of CKD versus patients with CKD 1+2 for mid-term mortality.\
A, Pooled univariate hazard ratio of advanced stages of CKD compared with CKD stage 1+2 for all-cause mid-term mortality. B, Pooled multivariate hazard ratio of advanced stages of CKD compared with CKD stage 1+2 for all-cause mid-term mortality. RD, renal dysfunction; CI, confidence interval; Random, Random-effects model; Fixed, fixed-effects model; IV, Generic Inverse Variance method.](pone.0119817.g007){#pone.0119817.g007}

A total of 9 studies that included 5,266 patients were eligible for the pooled analysis of baseline serum creatinine (for each increase of 1 mg/dl) with respect to mid-term outcomes \[[@pone.0119817.ref018], [@pone.0119817.ref037], [@pone.0119817.ref050]--[@pone.0119817.ref056]\] ([Fig. 8](#pone.0119817.g008){ref-type="fig"}). The cumulative mortality after TAVI was 24.1%. Each 1 mg/dl increase in serum creatinine significantly raised the mid-term all-cause mortality rate (pooled univariate HR: 1.24, 95% CI: 1.18--1.30; pooled multivariate HR: 1.19, 95% CI: 1.08--1.30). The pooled results remained stable when individual studies in the univariate model were omitted and also persisted in the multivariate analysis after removing the study that excluded patients with ESRD \[[@pone.0119817.ref018]\] (pooled multivariate HR: 1.24, 95% CI: 1.16--1.32).

![Forest plots of mid-term mortality associated with RD.\
A, Pooled univariate hazard ratio of patients without RD compared with patients with RD for all-cause mid-term mortality. B, Pooled multivariate hazard ratio of patients without RD compared with patients with RD for all-cause mid-term mortality. RD, renal dysfunction; CI, confidence interval; Fixed, fixed-effects model; Random, Random-effects model; IV, Generic Inverse Variance method.](pone.0119817.g008){#pone.0119817.g008}

The study by Le Ven et al \[[@pone.0119817.ref057]\] reported a similar finding with regard to baseline eGFR; specifically, each 10 ml/min decrease was found to be associated with a significantly higher risk of all-cause mortality after TAVI (univariate HR: 1.14, 95% CI: 1.07--1.22; multivariate HR: 1.14, 95% CI: 1.07--1.22).

Publication Bias {#sec020}
================

Although a subtle publication bias was observed in the funnel plot inspection comparing patients with RD (defined as decreased eGFR) with patients with normal renal function in the univariate model, the pooled estimates remained significant after implementing the "Trim and Fill" method. In the rest of the analyses, funnel plots, Begg's test and Egger's test did not provide clear evidence for publication bias ([S1](#pone.0119817.s002){ref-type="supplementary-material"}--[S5](#pone.0119817.s006){ref-type="supplementary-material"} Figs).

Discussion {#sec021}
==========

The present study is the first to conduct pooled analyses (using both univariate and multivariate models) of the mid-term prognostic value of RD after TAVI. Preexisting RD, despite different definitions, was found to be associated with significantly increased mid-term mortality. Although it has been clearly demonstrated that aging patients with symptomatic AS have a high prevalence of RD, only a few TAVI studies have treated RD as a component of the primary study question, and the results have been conflicting \[[@pone.0119817.ref006], [@pone.0119817.ref007], [@pone.0119817.ref010], [@pone.0119817.ref029], [@pone.0119817.ref044], [@pone.0119817.ref048], [@pone.0119817.ref049], [@pone.0119817.ref058]\]. By conducting this meta-analysis, we have clearly shown a correlation between mid-term outcome and baseline renal function, as reflected by either baseline eGFR or serum creatinine.

Varying degrees of RD, as classified by advanced stages of CKD, were associated with significantly higher incidences of bleeding, AKI, and mid-term mortality after TAVI. Post-procedural stroke occurred more frequently in patients with CKD stage 4 compared with CKD 1+2. These findings were in line with previous TAVI studies focusing on the peri-procedural complications \[[@pone.0119817.ref008], [@pone.0119817.ref044], [@pone.0119817.ref059]\]. However, differences about the incidence of MVC were not significant in our study. At mid-term follow-up, patients with CKD stage 4 were noted to have a poorer prognosis compared with patients with CKD stage 3. This graded association was further confirmed when considering baseline serum creatinine (for each 1 mg/mL decrease), which was also strongly related to increased mid-term mortality. In previous studies, advanced stages of CKD have been shown to be independent risk factors in patients undergoing TAVI \[[@pone.0119817.ref010], [@pone.0119817.ref029], [@pone.0119817.ref049]\]. However, no stepwise increased adverse events was observed in patients with more severe CKD \[[@pone.0119817.ref010], [@pone.0119817.ref029]\]. By pooling estimate effects from these individual studies, we found that patients with CKD stage 4 had significantly higher incidence of AKI and mortality rates compared with those with CKD stage 3. Because patients with ESRD have been excluded from many TAVI studies, only sparse data exist on the prognostic value of CKD stage 5 \[[@pone.0119817.ref029], [@pone.0119817.ref060]\]. In the present study, pre-procedural chronic dialysis was also shown to be a strong risk factor for mid-term mortality after TAVI.

The presence of RD is an important factor contributing to poorer outcomes in patients undergoing TAVI. This phenomenon can be explained by several aspects. (1) Patients with RD were older, were frailer, and presented with a significantly higher Logistic Euroscore in previous studies \[[@pone.0119817.ref010], [@pone.0119817.ref029], [@pone.0119817.ref049]\]. In view of these data, RD may serve as a marker of unbalanced baseline risk profiles. Patients with RD frequently have a higher burden of severe morbidities, which may adversely affect their survival after TAVI. (2) RD modifies the natural history of AS, presumably through a pathophysiological mechanism that promotes calcium deposition on aortic leaflets, thereby worsening aortic stenosis and reducing cardiac output \[[@pone.0119817.ref061]\]. Severe AS with decreased flow to important organs is responsible for the onset of severe complications, which subsequently increase the mortality after TAVI \[[@pone.0119817.ref008], [@pone.0119817.ref048], [@pone.0119817.ref062]\]. RD was also found to be associated with disorders of primary hemostasis, in particular platelet malfunctions \[[@pone.0119817.ref063]\], which played an important role in the occurrence of peri-procedural bleeding and subsequently increased mortality \[[@pone.0119817.ref059]\]. (3) It is well known that one of the advantages of TAVI is the avoidance of cardiopulmonary bypass, which is one of the most important risk factors for post-procedural AKI \[[@pone.0119817.ref064]\]. However, the incidence of contrast-induced nephropathy (CIN) could conceivably increase as a result of the extensive use of contrast medium and multiple injections \[[@pone.0119817.ref065], [@pone.0119817.ref066]\]. Although few studies have identified a significant association between contrast agents and AKI in the general population \[[@pone.0119817.ref067], [@pone.0119817.ref068]\], when focusing on patients with RD, the incidence of CIN was found to be significantly enhanced. Among patients with CKD, the occurrence of CIN was strongly associated with a higher 60-day mortality \[[@pone.0119817.ref069]\], indicating that the nephrotoxic mechanisms of CIN were one of the major issues contributing to the mid-term mortality in such patients.

In patients with more severe kidney failure, a higher Logistic Euroscore and lower ejection fraction were more frequent \[[@pone.0119817.ref010], [@pone.0119817.ref029]\]. Moreover, the incidence of post-procedural renal impairment was also significantly higher in patients with more severe RD, despite using a smaller dose of contrast medium \[[@pone.0119817.ref029]\]. These results could explain the graded association between the severity of RD and the stepwise increase in mortality after TAVI.

In view of these data, RD appears to be not only a marker of illness severity, but it also represents a risk factor for mid-term prognosis. Therefore, rigorous risk assessment, preventive therapies for bleeding and stroke, and timely detection of AKI would be crucial interventions that would improve the mid-term mortality after TAVI. Our study revealed higher incidence of peri-procedural complications and poorer outcomes in patients with CKD stage 4. However, this result also raises questions regarding whether these high-risk patients actually benefit from a TAVI procedure and which patients are at the highest risk of mid-term mortality.

Limitations {#sec022}
===========

Several limitations exist in our study. (1) Because the present meta-analysis was based only on published studies, the possibility of potential publication bias cannot be completely ruled out. (2) Although careful screening was conducted, the possibility of overlapping study populations could result in similar estimates. (3) Our meta-analysis was not conducted at the patient level, and only 5 studies treated RD as the primary study question. Even though the renal function-specific baseline characteristics were not available, the effects of comorbidities could not be assessed. (4) The adjusted prognostic value of different degrees of RD on the mid-term mortality after TAVI was not assessed due to the scarcity of study data. (5) Most included studies calculated eGFR using the MDRD equation, which is affected by the considerable decline in muscle mass with age, severe cardiovascular disease, drugs, and diet, making it difficult to reflect the actual renal clearance in the cohort of elderly patients.

Conclusions {#sec023}
===========

Preexisting RD, despite different definitions, was associated with significantly increased mid-term mortality after TAVI. Varying degrees of RD were strongly associated with a stepwise increase in mid-term mortality rates. Given that patients with CKD stage 4 had a higher incidence of peri-procedural complications and a poorer prognosis, TAVI in such patients may present a significant challenge.
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###### 

(DOC)

###### 

Click here for additional data file.

###### Funnel plots of comparison between RD (defined by the author) and normal renal function for mid-term mortality.

A, Comparison in univariable model (Begg's test: P = 0.23; Egger's test: P = 0.208; Trim and Fill Analysis not performed). B, Comparison in multivariable model. (Begg's test: P = 0.548; Egger's test: P = 0.215; Trim and Fill Analysis not performed).

(TIF)

###### 

Click here for additional data file.

###### Funnel plots of comparison between RD (defined as decreased eGFR) and normal renal function for mid-term mortality.

A, Comparison in univariable model. (Begg's test: P = 0.119; Egger's test: P = 0.129; Trim and Fill Analysis not performed). B, Comparison in multivariable model. (Begg's test: P = 0.133; Egger's test: P = 0.06; Trim and Fill Analysis: Pooled estimate = 0.306, P\<0.001).

(TIF)

###### 

Click here for additional data file.

###### Funnel plots of comparison between RD (defined as increased Serum creatinine) and normal renal function for mid-term mortality.

A, Comparison in univariable model. (Begg's test: P = 0.711; Egger's test: P = 0.711; Trim and Fill Analysis not performed). B, Comparison in multivariable model. (Begg's test: P = 0.133; Egger's test: P = 0.086; Trim and Fill Analysis: Pooled estimate = 0.436, P\<0.001).

(TIF)

###### 

Click here for additional data file.

###### Funnel plots of comparison between CKD stage 5 and CKD stage 1+2 for mid-term mortality.

Begg's test: P = 0.806; Egger's test: P = 0.841; Trim and Fill Analysis not performed.

(TIF)

###### 

Click here for additional data file.

###### Funnel plots for the impact of baseline serum creatinine (for each increase of 1 mg/dl) on the mid-term mortality.

A, Preformed in univariable model. (Begg's test: P = 0.902; Egger's test: P = 0.430; Trim and Fill Analysis not performed). B, Preformed in multivariable model. (Begg's test: P = 0.764; Egger's test: P = 0.507; Trim and Fill Analysis not performed).

(TIF)

###### 

Click here for additional data file.
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